Yesterday DKTI made an announcement regarding the ongoing talks with Dandrit A/S. Apparantly the status of DKTI a7s as an investment company raises some tax-issues with regard to the proposed merger.
The solution has therefore been that Dandrit shareholders get new shares in DKTI A/S (a swap if you will). General Assembly to be held in Q3.
Effectively this is the birth of a new danish listed company, researching in cutting-edge technology within the very attractive onchology area. And a company that is working with cancer vaccine
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=512135&lang=da
